Prasopsiri J, Srisutthisamphan K, Liwnaree B, Jengarn J, Kramyu J, Hansoongnern P
Vaccines (Basel). 2025; 13(1.
PMID: 39852781
PMC: 11768598.
DOI: 10.3390/vaccines13010002.
Antonelli R, Forconi V, Molesti E, Semplici C, Piu P, Altamura M
F1000Res. 2024; 13:534.
PMID: 39512237
PMC: 11541077.
DOI: 10.12688/f1000research.149578.2.
Alessandra R, Sara C, Claudia P, Natasha G, Federica C, Chiara B
J Transl Med. 2024; 22(1):755.
PMID: 39135151
PMC: 11318244.
DOI: 10.1186/s12967-024-05556-2.
Baker Jr R, Lawlor R, Smith M, Price J, Eaton A, Lover A
Front Immunol. 2024; 15:1401209.
PMID: 38812500
PMC: 11133519.
DOI: 10.3389/fimmu.2024.1401209.
Phiri K, Grill L
Vaccines (Basel). 2024; 12(5).
PMID: 38793699
PMC: 11125883.
DOI: 10.3390/vaccines12050448.
Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine.
Dashti N, Golsaz-Shirazi F, Soltanghoraee H, Zarnani A, Mohammadi M, Imani D
Eur J Microbiol Immunol (Bp). 2024; 14(3):228-242.
PMID: 38753442
PMC: 11393645.
DOI: 10.1556/1886.2024.00045.
Altered transcriptomic immune responses of maintenance hemodialysis patients to the COVID-19 mRNA vaccine.
Chang Y, Huang K, Lee J, Vagts C, Ascoli C, Amin M
Elife. 2024; 13.
PMID: 38656290
PMC: 11042800.
DOI: 10.7554/eLife.83641.
SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice.
Pavan M, Bok M, Betanzos San Juan R, Malito J, Marcoppido G, Franco D
Viruses. 2024; 16(2).
PMID: 38399961
PMC: 10892724.
DOI: 10.3390/v16020185.
A pan-influenza monoclonal antibody neutralizes H5 strains and prophylactically protects through intranasal administration.
Beukenhorst A, Frallicciardi J, Rice K, Koldijk M, Moreira de Mello J, Klap J
Sci Rep. 2024; 14(1):3818.
PMID: 38360813
PMC: 10869794.
DOI: 10.1038/s41598-024-53049-5.
Immunological insights into COVID-19 in Southern Nigeria.
Ugwu C, Alao O, John O, Akinnawo B, Ajayi I, Odebode O
Front Immunol. 2024; 15:1305586.
PMID: 38322252
PMC: 10844438.
DOI: 10.3389/fimmu.2024.1305586.
Serological evidence of virus infection in fruit bats: implications for bushmeat consumption in Nigeria.
Cantoni D, Mayora-Neto M, Derveni M, da Costa K, Del Rosario J, Ameh V
Front Public Health. 2023; 11:1283113.
PMID: 38106901
PMC: 10723585.
DOI: 10.3389/fpubh.2023.1283113.
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study.
Cole J, Capala-Szczurko I, Roseti S, Chen C, Caveney S, Aksyuk A
Pulm Ther. 2023; 10(1):53-67.
PMID: 38064153
PMC: 10881940.
DOI: 10.1007/s41030-023-00245-9.
Deep mutagenesis scanning using whole trimeric SARS-CoV-2 spike highlights the importance of NTD-RBD interactions in determining spike phenotype.
Kugathasan R, Sukhova K, Moshe M, Kellam P, Barclay W
PLoS Pathog. 2023; 19(8):e1011545.
PMID: 37535672
PMC: 10426949.
DOI: 10.1371/journal.ppat.1011545.
YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge.
Lemmens V, Kelchtermans L, Debaveye S, Chiu W, Vercruysse T, Ma J
NPJ Vaccines. 2023; 8(1):99.
PMID: 37433816
PMC: 10336040.
DOI: 10.1038/s41541-023-00699-7.
The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11.
Tolbert W, Chen Y, Sun L, Benlarbi M, Ding S, Manickam R
Front Immunol. 2023; 14:1178355.
PMID: 37334379
PMC: 10272436.
DOI: 10.3389/fimmu.2023.1178355.
Hybrid immunity in older adults is associated with reduced SARS-CoV-2 infections following BNT162b2 COVID-19 immunisation.
Pallett S, Heskin J, Keating F, Mazzella A, Taylor H, Patel A
Commun Med (Lond). 2023; 3(1):83.
PMID: 37328651
PMC: 10275930.
DOI: 10.1038/s43856-023-00303-y.
Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice.
Prompetchara E, Ketloy C, Alameh M, Tharakhet K, Kaewpang P, Yostrerat N
Nat Commun. 2023; 14(1):2309.
PMID: 37085495
PMC: 10120480.
DOI: 10.1038/s41467-023-37795-0.
Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies.
Aguinam E, Nadesalingam A, Chan A, Smith P, Paloniemi M, Cantoni D
J Allergy Clin Immunol Glob. 2023; 2(2):100091.
PMID: 37038555
PMC: 10015741.
DOI: 10.1016/j.jacig.2023.100091.
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
Horvath D, Temperton N, Mayora-Neto M, da Costa K, Cantoni D, Horlacher R
Sci Rep. 2023; 13(1):4648.
PMID: 36944687
PMC: 10029786.
DOI: 10.1038/s41598-023-31198-3.
Pseudotyped Viruses for Influenza.
Del Rosario J, da Costa K, Temperton N
Adv Exp Med Biol. 2023; 1407:153-173.
PMID: 36920696
DOI: 10.1007/978-981-99-0113-5_8.